scholarly journals The Role of β-Arrestin Proteins in Organization of Signaling and Regulation of the AT1 Angiotensin Receptor

2019 ◽  
Vol 10 ◽  
Author(s):  
Gábor Turu ◽  
András Balla ◽  
László Hunyady
Keyword(s):  
Angiotensin Receptor

Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450

2016 ◽  
Vol 17 (7) ◽  
pp. 681-691 ◽  
Author(s):  
Ruirui Yang ◽  
Zhiqiang Luo ◽  
Yang Liu ◽  
Mohan Sun ◽  
Ling Zheng ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cytochromes P450 ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

scholarly journals The Role of Apelin on the Alleviative Effect of Angiotensin Receptor Blocker in Unilateral Ureteral Obstruction-Induced Renal Fibrosis

Nephron Extra ◽  
2012 ◽  
Vol 2 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Masashi Nishida ◽  
Yasuko Okumura ◽  
Tatsujiro Oka ◽  
Kentaro Toiyama ◽  
Seiichiro Ozawa ◽  
...  
Keyword(s):  
Ureteral Obstruction ◽  
Renal Fibrosis ◽  
Angiotensin Receptor Blocker ◽  
Unilateral Ureteral Obstruction ◽  
Receptor Blocker ◽  
Angiotensin Receptor

Heart Failure Therapy in 2016

2016 ◽  
Vol 51 (1) ◽  
pp. 79-82
Author(s):  
Douglas L. Jennings
Keyword(s):  
Heart Failure ◽  
Recent Literature ◽  
Residual Disease ◽  
Angiotensin Receptor ◽  
Heart Failure Therapy ◽  
Call To Action ◽  
Neprilysin Inhibitor ◽  
Drug Regimens ◽  
Contemporary Practice

Heart failure (HF) continues to afflict millions of Americans, resulting in substantial clinical and economic burden to our society. Recent literature has highlighted the role of 2 novel therapies (an angiotensin receptor blocker/neprilysin inhibitor and ivabradine) in further reducing residual disease in HF. Simultaneously, evidence has mounted suggesting that older therapies like digoxin are not effective in contemporary practice and, in fact, may be harmful. This editorial summarizes the most recently published articles pertaining to both new and old HF therapies and provides a call to action to pharmacists on how to shift patients toward effective drug regimens.

scholarly journals Azilsartan: Current Evidence and Perspectives in Management of Hypertension

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Akshyaya Pradhan ◽  
Ashish Tiwari ◽  
Rishi Sethi
Keyword(s):  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Financial Burden ◽  
Daily Practice ◽  
Current Evidence ◽  
Hypertension Management ◽  
Angiotensin Receptor ◽  
Global Pandemic ◽  
Receptor Blockers

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.

The Evolving Role of Angiotensin Receptor Blockers in Heart Failure

2002 ◽  
Vol 37 (5) ◽  
pp. 474-482
Author(s):  
Patricia A. Howard
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Cardiovascular Pharmacotherapy ◽  
The Us ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Receptor Blockers

This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.

Sign in / Sign up

Export Citation Format

Share Document